STAT
SEPTEMBER 18, 2024
patent system by the pharmaceutical industry, moves by some drugmakers to expand their patent claims appear to be delaying the arrival of lower-cost generic medicines to the marketplace, according to a STAT analysis. Amid debate over potential abuse of the U.S.
STAT
SEPTEMBER 14, 2023
In explaining its new policy statement , the FTC noted that some drug companies have failed to follow requirements for listing patents in the so-called Orange Book in hopes of thwarting competition from lower-cost generic medicines. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 7, 2023
The move comes two months after the FTC issued a policy statement noting some drug companies have failed to follow requirements for listing patents in the Food and Drug Administration’s Orange Book in hopes of thwarting competition from lower-cost generic medicines. Continue to STAT+ to read the full story…
Express Pharma
MARCH 12, 2025
It noted that US law requires complete manufacturing addresses to be printed on generic drug packaging and listed in the FDAs Orange Book database. The FDA has an established office in India overseeing the number of qualified manufacturers supplying generic medicines to the US.
PharmaState Academy
JANUARY 29, 2024
Significance of the Indian Pharmaceutical Market: Discussing the Indian pharmaceutical market, Mr. Kapadia noted India’s status as the world’s largest exporter of generic medicines and third in terms of pharmaceutical production.
Quality Matters
JUNE 26, 2023
Complex generics: Are global regulators addressing the needs? The development of generic versions of innovator medicines is a global public health need. To address this challenge and to support the development of generic versions of NBCPs, as well as assist manufacturers in planning of required studies for approval, the U.S.
Express Pharma
SEPTEMBER 11, 2023
This move unburdened the private pharma companies allowing them to concentrate and strengthen their base, and they succeeded in gaining a national as well as international market presence as “global generic medicine manufacturers.” Rating BX: Awarded to generic products presumed to be therapeutically non-equivalent.
Expert insights. Personalized for you.
356 
Let's personalize your content